6 versus 12 months of adjuvant trastuzumab for HER2-positive early

trastuzumab If you're having trastuzumab to treat primary breast cancer after surgery, it's usually given for 1 year Some people may be offered

Trastuzumab emtansine is a HER2-targeted, microtubule-stabilizing antibody-drug conjugate with about 3 chemotherapy molecules per antibody trastuzumab Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and